Septerna (NASDAQ:SEPN) Trading 10.3% Higher – Should You Buy?

Shares of Septerna, Inc. (NASDAQ:SEPN) traded up 10.3% during trading on Tuesday . The stock traded as high as $36.98 and last traded at $36.9040. 134,133 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 338,672 shares. The stock had previously closed at $33.47.

Analyst Ratings Changes

SEPN has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Septerna in a research note on Wednesday, July 1st. Raymond James Financial boosted their price objective on Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research report on Monday, June 8th. JPMorgan Chase & Co. lifted their price target on shares of Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. Truist Financial increased their price objective on shares of Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Finally, Wall Street Zen downgraded shares of Septerna from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $45.89.

Septerna Trading Up 9.1%

The stock’s 50 day moving average is $30.23 and its two-hundred day moving average is $27.71. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -45.14 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. The firm had revenue of $26.52 million for the quarter, compared to analyst estimates of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. On average, sell-side analysts predict that Septerna, Inc. will post -1.59 EPS for the current year.

Insider Buying and Selling at Septerna

In related news, SVP Daniel D. Long sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $35.51, for a total value of $532,650.00. Following the completion of the transaction, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,423,590.12. This trade represents a 13.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Samira Shaikhly sold 11,798 shares of the firm’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total value of $354,647.88. Following the completion of the transaction, the insider owned 793 shares of the company’s stock, valued at approximately $23,837.58. This represents a 93.70% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 48,494 shares of company stock valued at $1,566,751. Corporate insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Septerna

Several hedge funds have recently made changes to their positions in SEPN. Group One Trading LLC lifted its holdings in shares of Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after acquiring an additional 8,955 shares in the last quarter. Global Retirement Partners LLC purchased a new position in shares of Septerna during the 4th quarter valued at approximately $35,000. Russell Investments Group Ltd. acquired a new stake in shares of Septerna during the third quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Septerna in the fourth quarter worth $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Septerna in the fourth quarter valued at $61,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.